Clinical Trial Update: An Open Trial to Assess the Tolerability of AVANZ Phleum Pratense Immunotherapy [Phase 2, Phase 3]

View source ↗

Summary

This update reports results from an open Phase 2/Phase 3 trial evaluating the tolerability of AVANZ Phleum pratense immunotherapy for allergic rhinoconjunctivit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Rhinoconjunctivitis

Drugs mentioned

• AVANZ Phleum Pratense Immunotherapy (timothy grass pollen immunotherapy)

Snippet

Sponsor: ALK-Abelló A/S | Conditions: Allergic Rhinoconjunctivitis | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2015-03-06